SG Americas Securities LLC Buys New Position in Generation Bio Co. (NASDAQ:GBIO)

SG Americas Securities LLC bought a new stake in shares of Generation Bio Co. (NASDAQ:GBIO) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 22,014 shares of the company’s stock, valued at approximately $552,000.

Several other large investors also recently made changes to their positions in GBIO. Yiheng Capital Management L.P. purchased a new stake in shares of Generation Bio during the 2nd quarter valued at about $38,103,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Generation Bio by 13.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,363,115 shares of the company’s stock valued at $198,068,000 after buying an additional 878,571 shares during the period. Vanguard Group Inc. raised its holdings in shares of Generation Bio by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,225,326 shares of the company’s stock valued at $86,761,000 after buying an additional 289,944 shares during the period. Morgan Stanley raised its holdings in shares of Generation Bio by 40,459.5% during the 2nd quarter. Morgan Stanley now owns 254,308 shares of the company’s stock valued at $6,841,000 after buying an additional 253,681 shares during the period. Finally, State Street Corp raised its holdings in shares of Generation Bio by 6.2% during the 2nd quarter. State Street Corp now owns 2,244,201 shares of the company’s stock valued at $60,369,000 after buying an additional 131,574 shares during the period. Institutional investors and hedge funds own 84.32% of the company’s stock.

Several research firms have issued reports on GBIO. Needham & Company LLC dropped their price objective on Generation Bio from $50.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, December 15th. JPMorgan Chase & Co. downgraded Generation Bio from an “overweight” rating to a “neutral” rating in a report on Wednesday, December 15th. JMP Securities dropped their price objective on Generation Bio from $40.00 to $10.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 15th. William Blair downgraded Generation Bio from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 14th. Finally, Zacks Investment Research upgraded Generation Bio from a “sell” rating to a “hold” rating in a report on Tuesday, November 16th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $30.25.

Shares of GBIO opened at $6.97 on Friday. The firm has a market cap of $396.66 million, a price-to-earnings ratio of -3.32 and a beta of 3.50. The stock has a 50 day moving average of $12.73 and a 200-day moving average of $19.96. Generation Bio Co. has a 52 week low of $5.50 and a 52 week high of $41.86.

Generation Bio (NASDAQ:GBIO) last issued its earnings results on Wednesday, November 10th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.02). As a group, sell-side analysts forecast that Generation Bio Co. will post -2.14 EPS for the current year.

About Generation Bio

Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Featured Article: S&P/ASX 200 Index

Want to see what other hedge funds are holding GBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Generation Bio Co. (NASDAQ:GBIO).

Institutional Ownership by Quarter for Generation Bio (NASDAQ:GBIO)

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.